Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Lung04: Trastuzumab Deruxtecan in First-line HER2-mutated NSCLC
NCT05048797Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Oct 2021; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05048797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048797.